Friction in the Path to Use of Biosimilar Drugs

Frank, Richard G.

doi:10.1056/nejmp1714908

Cited by 14 publications

(5 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Uptake of biosimilar filgrastim in the Medicare Part B program occurred despite multiple challenges to the adoption of biosimilars in the US market, [15][16][17] suggesting that substantial potential savings could be generated by promoting biosimilar uptake. Our findings indicated that biosimilar uptake is a decision made at the facility level and that physician practices and HOPDs have distinctive biosimilar uptake patterns.…”

Section: Discussionmentioning

confidence: 99%

Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim

et al. 2020

View full text Add to dashboard Cite

and compare characteristics of patients and facilities that used filgrastim-sndz or originator filgrastim (Neupogen).Methods: The 20% sample of Medicare Part B fee-for-service administrative claims data was used to extract information on claims for any filgrastim product between January 1, 2015 and December 31, 2017.Results: The utilization of filgrastim-sndz in Medicare Part B increased sharply between January and August 2016, surpassing filgrastim by November 2017, contributing to a 30% decrease in overall spending on this drug since 2015. Uptake was faster and larger in physician practices compared with hospital outpatient departments. About 77% of patients receiving filgrastimsndz were new users. Utilization patterns indicated that product selection occurred at the facility level, rather than being at the discretion of the prescribing physician or driven by patient characteristics. Conclusion:Uptake of biosimilar filgrastim in the Medicare Part B program occurred despite multiple challenges to the adoption of biosimilars in the US market, suggesting that substantial potential savings could be generated by improving biosimilar uptake. Our findings indicated that physician practices and hospital outpatient departments have distinctive biosimilar uptake patterns. Thus policy makers aiming to contain Medicare Part B spending might consider focusing on incentivizing biosimilar uptake among hospital outpatient departments.

show abstract

Section: Discussionmentioning

confidence: 99%

Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The atmosphere around biosimilars in the US is so poisoned by misinformation and political turmoil, that US prescribers have little confidence in biosimilars. 19 As explained before, in Europe the situation is completely different. In 2016 there were 700 million patient biosimilar treatment days without complications.…”

Section: Outlook and Recommendationsmentioning

confidence: 95%

“…Of the 17 US‐licensed biosimilars, only 7 are available on the market, and only 2 are more or less a commercial success. The atmosphere around biosimilars in the US is so poisoned by misinformation and political turmoil, that US prescribers have little confidence in biosimilars 19 …”

Section: Outlook and Recommendationsmentioning

confidence: 99%

Biologicals and Biosimilars in Hematology: The Case of Rituximab

Vulto

2019

HemaSphere

View full text Add to dashboard Cite

“…These data highlight the importance of biosimilars in making treatments available for reimbursement when they may otherwise be unaffordable [69]. However, in the USA, the introduction of biosimilars has yet to deliver significant cost savings, which may be achievable through changes to current legislation and policies concerning patent litigation, naming of biosimilars, and the interchangeability, formulary listing and rebate schemes of biological reference drugs and their biosimilar counterparts [58,65,[70][71][72][73].…”

Section: Biosimilar Filgrastimmentioning

confidence: 99%

The Evolution of Value With Filgrastim in Oncology

Cornes

Krendyukov

2019

Future Oncol.

View full text Add to dashboard Cite

The recombinant G-CSF filgrastim was first approved in 1991, and its value has been evolving ever since. Initial health technology assessments suggested low value due to high drug cost and no evidence for significant gain in overall survival. However, more recent meta-analyses of placebo-controlled randomized trial data show falling costs due to biosimilar competition and absolute overall survival gains of 3.2% (95% CI: 2.1-4.2%) from filgrastim support of cytotoxic chemotherapy. The launch of biosimilar alternatives merits a re-evaluation of decisions by health technology assessments and explains the first inclusion of filgrastim in the WHO Essential Drug List for cancer >20 years after its original approval in 1991, thus demonstrating the power of biosimilar medicines in transforming healthcare.

show abstract

Friction in the Path to Use of Biosimilar Drugs

Cited by 14 publications

References 2 publications

Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim

Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim

Biologicals and Biosimilars in Hematology: The Case of Rituximab

The Evolution of Value With Filgrastim in Oncology

Contact Info

Product

Resources

About